Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size

BACKGROUND: Since December 2019, COVID-19 has spread to almost every corner of the world. In theory, tocilizumab and favipiravir are considered to be reliable drugs for the treatment of COVID-19 with elevated IL-6. We aimed to assess the efficacy and safety of tocilizumab combined with favipiravir i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Hong, Zhu, Qi, Zhang, Chi, Li, Jiawen, Wei, Ming, Qin, Yuhong, Chen, Guilin, Wang, Ke, Yu, Junhua, Wu, Zhao, Chen, Xianxiang, Wang, Guiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Masson SAS. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524677/
https://www.ncbi.nlm.nih.gov/pubmed/33378989
http://dx.doi.org/10.1016/j.biopha.2020.110825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524677/
https://www.ncbi.nlm.nih.gov/pubmed/33378989
http://dx.doi.org/10.1016/j.biopha.2020.110825

Ejemplares similares